Navigation Links
Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
Date:4/11/2013

SUNNYVALE, Calif., April 11, 2013 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that patient dosing has commenced in its Phase 2b clinical trial of CLP-1001.  This trial, known as STEPWISE (a randomized, double-blind, multi-center STudy comparing cross-linkEd Polyelectrolyte (CLP) WIth placebo in HF SubjEcts), is designed to evaluate the safety and efficacy of CLP-1001 in addressing signs and symptoms of fluid overload in patients with congestive heart failure (HF).  CLP-1001 is a novel, non-absorbed oral polymer that acts by binding to and removing excess sodium and fluid in the GI tract independently of the kidneys.

"The objective of the STEPWISE trial is to further understand the magnitude of the effect of CLP-1001 on key measures and clinical endpoints of heart failure-induced congestion compared to current standard of care," said Howard C. Dittrich , M.D., F.A.C.C., Chief Medical Officer of Sorbent.  "Fluid overload in heart failure patients contributes importantly to hospitalizations -- including re-hospitalizations -- slows in-patient recovery, and results in poor quality of life and physical limitations.  Based on the positive clinical benefits observed in our Phase 2a clinical trial, we look forward to advancing CLP-1001 through late-stage registration studies."   

STEPWISE is a double-blind, randomized, placebo-controlled, multicenter, study designed to evaluate CLP-1001 in patients with heart failure.  Approximately 250 patients on stable, optimized, guideline heart failure therapy that have signs and symptoms of current fluid overload after a recent HF-related hospitalization will be randomized to receive 15 grams of CLP-1001 or placebo.  The primary objective of this trial is to assess the change from baseline to eight weeks across sever
'/>"/>

SOURCE Sorbent Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
2. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
3. Sorbent Therapeutics Appoints Jason Levin Chief Business Officer
4. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
5. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ... to maintain the anatomical reduction (spacing) of the scaphoid ...
(Date:1/14/2014)... , Jan. 14, 2014 NineSigma , ... hold its Innovation Leadership Summit , May 14-16, ... Cleveland Ohio . ... and organizations committed to breakthrough achievements through open innovation. ... through unobvious connections, across disciplines and even across industries. ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading ... announced that the Center for Drug Evaluation and ... released its first draft qualification guidance document for ... Qualification of Exacerbations of Chronic Pulmonary Disease ... Bacterial Exacerbation of Chronic Bronchitis in Patients With ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... CHICAGO, Oct. 7 A new women,s health, whole ... frequency of moderate to severe hot flashes and reduced ... its kind among postmenopausal U.S. women, according to peer-reviewed ... American Menopause Society (NAMS) Annual Meeting.  Also, the first ...
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Application (NDA) filing for carfilzomib based on a recent ... division of the U.S. Food and Drug Administration (FDA). ... commercial-scale manufacturing of carfilzomib.  Onyx had previously anticipated filing ...
Cached Medicine Technology:New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women 2New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women 3New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women 4New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women 5New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women 6New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women 7Onyx Pharmaceuticals Provides Status Update on Carfilzomib 2Onyx Pharmaceuticals Provides Status Update on Carfilzomib 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... stems from discovery of mutation affecting infertility, , , THURSDAY, ... infertility in men could point the way to a ... , "We have identified CATSPER1 as a gene that ... finding which could lead to future infertility therapies that ...
... a computer based model that aids them in discriminating ... study performed at the University Of Wisconsin School of ... multidisciplinary group, including radiologists and industrial engineers, led by ... Chhatwal, PhD. , "The computer based ...
... When the need for speed is critical, how ... hospitals, sending alerts to help prevent or stop a ... providers be notified about disease outbreaks, illness from food ... , Researchers from the Regenstrief Institute, Inc. in collaboration ...
... to Help Healthcare Organizations Improve Access to ... Systems OutageWAYNE, Pa. and GREENWOOD VILLAGE, Colo., ... formed a partnership with Orchestrate Healthcare, a ... to help healthcare organizations improve information availability ...
... not been proven that long-acting insulin analogues (LAIAs) have an ... with type 2 diabetes. Even though the results of a ... assessed (insulin glargine), the potential long-term benefits and harms of ... is the conclusion of a report by the German Institute ...
... on the success of Mirixa Corporation in the ... available nationwide in Australia GOLD COAST, Queensland, ... leader in pharmacy-based patient care services and the ... of Mirixa Australia at the Australian Pharmacy Professional ...
Cached Medicine News:Health News:Genetic Finding May Lead to Male Contraceptive 2Health News:Computer based model helps radiologists diagnose breast cancer 2Health News:Getting the word out when the need for speed is critical to public health 2Health News:Getting the word out when the need for speed is critical to public health 3Health News:SunGard Availability Services Partners with Orchestrate Healthcare to Improve Availability of Electronic Medical Records 2Health News:SunGard Availability Services Partners with Orchestrate Healthcare to Improve Availability of Electronic Medical Records 3Health News:SunGard Availability Services Partners with Orchestrate Healthcare to Improve Availability of Electronic Medical Records 4Health News:Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not proven 2Health News:Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not proven 3Health News:Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not proven 4Health News:Mirixa Australia Launches at APP2009 2Health News:Mirixa Australia Launches at APP2009 3
... System supports approaches to Admitting/Discharge/Transfer ... record keeping functions using a ... facilities and cut across institutional ... community clinics, physician, agency, nursing ...
... Dairylands Clinical Information Management ... suite of integrated applications ... departments and automate administrative ... The applications allow organizations ...
... include a Patient Face Sheet, ... many as six custom tabs, ... information is important for you ... Import Manager utility lets you ...
... WEBeDoctor® Physician-office® is an ... physicians, (Solo practice, group ... to complete their normal ... It is a front ...
Medicine Products: